{"id":"W3031554237","doi":"10.1016/j.jaad.2020.05.105","title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"UCB","keywords":"Medicine; Double blinded; Placebo; Plaque psoriasis; Randomized controlled trial; Blinded study; Dermatology; Psoriasis; Physical therapy; Surgery; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000467426,0.0004201302,0.002780794,0.0002308975,0.0002299516,0.00001900118,0.0006892398,0.0002238247,0.00002277623],"category_scores_gemma":[0.0004698861,0.0002429164,0.0005535195,0.0003644094,0.0003511558,0.0001688212,0.0001347614,0.0005105363,0.00001700393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004980823,"about_ca_system_score_gemma":0.0001798006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008619007,"about_ca_topic_score_gemma":0.00000845603,"domain_scores_codex":[0.9960784,0.001255086,0.001565018,0.0004524102,0.0001839464,0.0004650989],"domain_scores_gemma":[0.9948281,0.001698829,0.00282834,0.0002561534,0.0002594415,0.0001291535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9810093,0.001689082,0.0007439029,0.00001102946,0.00421258,0.00002784616,0.002077919,0.000422367,0.002290833,0.00001887162,0.005306126,0.002190121],"study_design_scores_gemma":[0.9783298,0.003265223,0.0008264471,0.00007439254,0.002666687,0.0002695895,0.001081708,0.00008905885,0.01129079,0.0001082462,0.001676135,0.0003219529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791924,0.0005915922,0.0003792703,0.01592203,0.0003604603,0.003130223,0.00036762,0.00002297998,0.00003344551],"genre_scores_gemma":[0.9966294,0.000106789,0.0009677488,0.001933138,0.00009540585,0.0001346898,0.00003012968,0.00003872765,0.00006403184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01743696,"threshold_uncertainty_score":0.9905846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03360327941764896,"score_gpt":0.2916476084855545,"score_spread":0.2580443290679055,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}